BridgeMD
New treatment option for Diffuse Large B Cell Lymphoma (DLBCL)
Official title Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
ClinicalTrials.gov ID: NCT07371923
What this study is testing
What is Zanubrutinib+Pola-R-CHP?
Zanubrutinib+Pola-R-CHP is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for diffuse large b cell lymphoma (dlbcl).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Currently, the first-line treatment regimen based on R-CHOP can only achieve clinical cure for 50% to 60% of patients.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Pathologically confirmed diffuse large B-cell lymphoma (DLBCL);
- Have a "measurable lesions" ;
- Have at least one of the following risk factors, including: IPI score ≥2 points, ABC subtype, double-expressor lymphoma, double-hit lymphoma...
- ECOG score 0-3;
- Expected survival time for 3 months or more;
You likely can't join if
- (the subject should not have any one of the following):
- currently suffering from other malignant tumor;
- ever received any treatments for lymphoma, except for short-term use of corticosteroids;
- Allergic to any kind of study drug;
- Active infection or uncontrol of HBV infection, HIV/AIDS or other serious infectious diseases;
- Pregnancy and lactation women of childbearing age and are reluctant to take contraception people;
See the full eligibility criteria
- Pathologically confirmed diffuse large B-cell lymphoma (DLBCL);
- Have a "measurable lesions" ;
- Have at least one of the following risk factors, including: IPI score ≥2 points, ABC subtype, double-expressor lymphoma, double-hit lymphoma, CD5-positive DLBCL, MCD subtype, N1 subtype, A53 subtype, extranodal lesions...
- ECOG score 0-3;
- Expected survival time for 3 months or more;
- White blood cell count ≥3 x 10e9/L, the platelet count≥50 x 10e9/L; 1.5 mg/dL or less of serum creatinine, creatinine clearance≥50 ml/min; ALT, AST 3 x ULN or less, total bilirubin 2 x ULN or less.
- (the subject should not have any one of the following):
- currently suffering from other malignant tumor;
- ever received any treatments for lymphoma, except for short-term use of corticosteroids;
- Allergic to any kind of study drug;
- Active infection or uncontrol of HBV infection, HIV/AIDS or other serious infectious diseases;
- Pregnancy and lactation women of childbearing age and are reluctant to take contraception people;
- Researchers think that the subject does not fit to participate in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.